Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications

Clinical Biochemistry

Volumn 46, Issue 6, 2013, Pages 466-479

  de Wit, Meike ^a   Fijneman, Remond J A ^a   Verheul, Henk M W ^a   Meijer, Gerrit A ^a   Jimenez, Connie R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Clinical needs; Colorectal cancer; Mass spectrometry; Proteins; Proteomics

Indexed keywords

PROTEOME; TUMOR MARKER; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER CELL CULTURE; CANCER STEM CELL; CELL FRACTIONATION; COLORECTAL CANCER; FECES ANALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SELECTED REACTION MONITORING MASS SPECTROMETRY; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR SPHEROID; COLON POLYPOSIS; COLORECTAL NEOPLASMS; CYTOLOGY; EXTRACELLULAR MATRIX; GENETICS; MICROSATELLITE INSTABILITY; PATHOLOGY; COLORECTAL TUMOR;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS; EXTRACELLULAR MATRIX; HUMANS; MASS SPECTROMETRY; MICROSATELLITE INSTABILITY; NEOPLASTIC STEM CELLS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84881259783     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.10.039     Document Type: Review

References (81)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. Shinya H., Wolff W.I. Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg 1979, 190:679-683.
4. The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
5. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
6. Jones S., Chen W.-D., Parmigiani G., Diehl F., Beerenwinkel N., Antal T., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008, 105:4283-4288.
7. Hermsen M., Postma C., Baak J., Weiss M., Rapallo A., Sciutto A., et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. YGAST 2002, 123:1109-1119.
8. Carvalho B., Postma C., Mongera S., Hopmans E., Diskin S., van de Wiel M.A., et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 2008, 58:79-89.
9. Carvalho B., Sillars-Hardebol A.H., Postma C., Mongera S., Droste J.T.S., Obulkasim A., et al. Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol (Dordr) 2012, 35:53-63.
10. Sillars-Hardebol A.H., Carvalho B., van Engeland M., Fijneman R.J.A., Meijer G.A. The adenoma hunt in colorectal cancer screening: defining the target. J Pathol 2012, 226:1-6.
11. Pino M.S., Chung D.C. The chromosomal instability pathway in colon cancer. YGAST 2010, 138:2059-2072.
12. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. YGAST 2010, 138:2073-2087.
13. Hoff G., Dominitz J.A. Contrasting US and European approaches to colorectal cancer screening: which is best?. Gut 2010, 59:407-414.
14. Sobin L., Hermanek P. International Union Against Cancer (UICC): TNM classification of malignant tumours 1987, 4th edition.
15. Van Cutsem E., Oliveira J., On behalf of the ESMO Guidelines Working Group Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2009, 20:iv49-iv50.
16. Impact B. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999, 17:1356-1363.
17. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358.
18. Van Cutsem E., Nordlinger B., Cervantes A., On behalf of the ESMO Guidelines Working Group Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010, 21:v93-v97.
19. Schirle M., Bantscheff M., Kuster B. Mass Spectrometry-Based Proteomics in Preclinical Drug Discovery. Chem Biol 2012, 19:72-84.
20. Yamashita K., Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 2009, 100:195-199.
21. Jimenez C.R., Knol J.C., Meijer G.A., Fijneman R.J.A. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics 2010, 73:1873-1895.
22. Barderas R., Babel I., Casal J.I. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl 2010, 4:159-178.
23. Pavlou M.P., Diamandis E.P. The cancer cell secretome: A good source for discovering biomarkers?. J Proteomics 2010, 73:1896-1906.
24. Wu C.-C., Hsu C.-W., Chen C.-D., Yu C.-J., Chang K.-P., Tai D.-I., et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010, 9:1100-1117.
25. Xue H., Lü B., Zhang J., Wu M., Huang Q., Wu Q., et al. Identification of Serum Biomarkers for Colorectal Cancer Metastasis Using a Differential Secretome Approach. J Proteome Res 2010, 9:545-555.
26. Luque-García J.L., Martínez-Torrecuadrada J.L., Epifano C., Cañamero M., Babel I., Casal J.I. Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics 2010, 10:940-952.
27. de Wit M., Jimenez C.R., Carvalho B., Belien J.A.M., Delis-van Diemen P.M., Mongera S., et al. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut 2012, 61:855-864.
28. Boisvert F.-M., Lam Y.W., Lamont D., Lamond A.I. A quantitative proteomics analysis of subcellular proteome localization and changes induced by DNA damage. Mol Cell Proteomics 2010, 9:457-470.
29. Flavin P., Redmond A., McBryan J., Cocchiglia S., Tibbitts P., Fahy-Browne P., et al. RuvBl2 cooperates with Ets2 to transcriptionally regulate hTERT in colon cancer. FEBS Lett 2011, 585:2537-2544.
30. Ali N.A., McKay M.J., Molloy M.P. Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Mol Biosyst 2010, 6:2332.
31. Ali N.A., Molloy M.P. Quantitative phosphoproteomics of transforming growth factor-β signaling in colon cancer cells. Proteomics 2011, 11:3390-3401.
32. Zhang J., Lou X., Yang S., He S., Yang L., Liu M., et al. BAG2 is a target of the c-Myc gene and is involved in cellular senescence via the p21CIP1 pathway. Cancer Lett 2012, 318:34-41.
33. Pocsfalvi G., Votta G., De Vincenzo A., Fiume I., Raj D.A.A., Marra G., et al. Analysis of Secretome Changes Uncovers an Autocrine/Paracrine Component in the Modulation of Cell Proliferation and Motility by c-Myc. J Proteome Res 2011, 10:5326-5337.
34. Wang Q., Chaerkady R., Wu J., Hwang H.J., Papadopoulos N., Kopelovich L., et al. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A 2011, 108:2444-2449.
35. Halvey P.J., Zhang B., Coffey R.J., Liebler D.C., Slebos R.J.C. Proteomic Consequences of a Single Gene Mutation in a Colorectal Cancer Model. J Proteome Res 2012, 11:1184-1195.
36. Halvey P.J., Ferrone C.R., Liebler D.C. GeLC-MRM Quantitation of Mutant KRAS Oncoprotein in Complex Biological Samples. J Proteome Res 2012, 11:3908-3913.
37. Di Palma S., Stange D., van de Wetering M., Clevers H., Heck A.J.R., Mohammed S. Highly Sensitive Proteome Analysis of FACS-Sorted Adult Colon Stem Cells. J Proteome Res 2011, 10:3814-3819.
38. Ang C.-S., Rothacker J., Patsiouras H., Burgess A.W., Nice E.C. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. J Chromatogr A 2010, 1217:3330-3340.
39. Zhu W., Fang C., Gramatikoff K., Niemeyer C.C., Smith J.W. Proteins and an Inflammatory Network Expressed in Colon Tumors. J Proteome Res 2011, 10:2129-2139.
40. Fijneman R.J.A., de Wit M., Pourghiasian M., Piersma S.R., Pham T.V., Warmoes M.O., et al. Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin Cancer Res 2012, 18:2613-2624.
41. Naba A. The matrisome: in silico definition and in vivo characterization by proteomics. Mol Cell Proteomics 2012, 11. [M111.014647].
42. Karagiannis G.S., Petraki C., Prassas I., Saraon P., Musrap N., Dimitromanolakis A., et al. Proteomic Signatures of the Desmoplastic Invasion Front Reveal Collagen Type XII as a Marker of Myofibroblastic Differentiation During Colorectal Cancer Metastasis. Oncotarget 2012, 3:267-285.
43. Cox J., Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem 2011, 80:273-299.
44. Hamelin C., Cornut E., Poirier F., Pons S., Beaulieu C., Charrier J.-P., et al. Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. FEBS J 2011, 278:4845-4859.
45. Xie L.-Q., Zhao C., Cai S.-J., Xu Y., Huang L.-Y., Bian J.-S., et al. Novel Proteomic Strategy Reveal Combined α 1Antitrypsin and Cathepsin D as Biomarkers for Colorectal Cancer Early Screening. J Proteome Res 2010, 9:4701-4709.
46. Kang U.-B., Yeom J., Kim H.-J., Kim H., Lee C. Expression profiling of more than 3500 proteins of MSS-type colorectal cancer by stable isotope labeling and mass spectrometry. J Proteomics 2012, 75:3050-3062.
47. Kim H.-J., Kang U.-B., Lee H., Jung J.-H., Lee S.-T., Yu M.-H., et al. Profiling of differentially expressed proteins in stage IV Colorectal cancers with good and poor outcomes. J Proteomics 2012, 75:2983-2997.
48. Tweedle E.M., Khattak I., Ang C.W., Nedjadi T., Jenkins R., Park B.K., et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut 2010, 59:1501-1510.
49. O'Dwyer D., Ralton L.D., O'Shea A., Murray G.I. The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis. PLoS One 2011, 6:e27718.
50. Jankova L., Chan C., Fung C.L.S., Song X., Kwun S.Y., Cowley M.J., et al. Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol Biosyst 2011, 7:2997-3005.
51. Besson D., Pavageau A.H., Valo I., Bourreau A., Belanger A., Eymerit-Morin C., et al. A Quantitative Proteomic Approach of the Different Stages of Colorectal Cancer Establishes OLFM4 as a New Nonmetastatic Tumor Marker. Mol Cell Proteomics 2011, 10. [M111.009712].
52. Wiśniewski J.R., Ostasiewicz P., Mann M. High Recovery FASP Applied to the Proteomic Analysis of Microdissected Formalin Fixed Paraffin Embedded Cancer Tissues Retrieves Known Colon Cancer Markers. J Proteome Res 2011, 10:3040-3049.
53. Yang H.-Y., Kwon J., Park H.-R., Kwon S.-O., Park Y.-K., Kim H.-S., et al. Comparative proteomic analysis for the insoluble fractions of colorectal cancer patients. J Proteomics 2012, 75:3639-3653.
54. Albrethsen J., Knol J.C., Piersma S.R., Pham T.V., de Wit M., Mongera S., et al. Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics 2010, 9:988-1005.
55. Chen J.-S., Chen K.-T., Fan C.-W., Han C.-L., Chen Y.-J., Yu J.-S., et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 2010, 277:3028-3038.
56. Han C.-L., Chen J.-S., Chan E.-C., Wu C.-P., Yu K.-H., Chen K.-T., et al. An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol Cell Proteomics 2011, 10. [M110.003087].
57. Choi D.-S., Park J.O., Jang S.C., Yoon Y.J., Jung J.W., Choi D.-Y., et al. Proteomic analysis of microvesicles derived from human colorectal cancer ascites. Proteomics 2011, 11:2745-2751.
58. Ang C.-S., Nice E.C. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res 2010, 9:4346-4355.
59. Ang C.-S., Rothacker J., Patsiouras H., Gibbs P., Burgess A.W., Nice E.C. Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis 2011, 32:1926-1938.
60. Bosch L.J., de Wit M., Oudgenoeg G., Hiemstra A., Mongera S., Piersma S.R., et al. Abstract 4523: Stool proteomics reveals new candidate biomarkers for colorectal cancer screening. Cancer Res 2012, 72:4523.
61. Bosch L.J.W., Carvalho B., Fijneman R.J.A., Jimenez C.R., Pinedo H.M., van Engeland M., et al. Molecular tests for colorectal cancer screening. Clin Colorectal Cancer 2011, 10:8-23.
62. Medema J.P., Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011, 474:318-326.
63. Fang D.D., Kim Y.J., Lee C.N., Aggarwal S., McKinnon K., Mesmer D., et al. Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer 2010, 102:1265-1275.
64. Van Houdt W.J., Emmink B.L., Pham T.V., Piersma S.R., Verheem A., Vries R.G., et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics 2011, 10. [M111.011353].
65. Pham T.V., Piersma S.R., Oudgenoeg G., Jimenez C.R. Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev Mol Diagn 2012, 12:343-359.
66. Lanza G., Ferracin M., Gafà R., Veronese A., Spizzo R., Pichiorri F., et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007, 6:54.
67. Schwenk J.M., Igel U., Neiman M., Langen H., Becker C., Bjartell A., et al. Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. Mol Cell Proteomics 2010, 9:2497-2507.
68. Picotti P., Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012, 9:555-566.
69. Mathivanan S., Lim J.W.E., Tauro B.J., Ji H., Moritz R.L., Simpson R.J. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 2010, 9:197-208.
70. Bauer K.M., Lambert P.A., Hummon A.B. Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil. Proteomics 2012, 12:1928-1937.
71. Fung K.Y.C., Brierley G.V., Henderson S., Hoffmann P., McColl S.R., Lockett T., et al. Butyrate-Induced Apoptosis in HCT116 Colorectal Cancer Cells Includes Induction of a Cell Stress Response. J Proteome Res 2011, 10:1860-1869.
72. Ghosh D., Yu H., Tan X.F., Lim T.K., Zubaidah R.M., Tan H.T., et al. Identification of Key Players for Colorectal Cancer Metastasis by iTRAQ Quantitative Proteomics Profiling of Isogenic SW480 and SW620 Cell Lines. J Proteome Res 2011, 10:4373-4387.
73. Organ S.L., Tong J., Taylor P., St-Germain J.R., Navab R., Moran M.F., et al. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. J Proteome Res 2011, 10:3200-3211.
74. Ikonomou G., Kostourou V., Shirasawa S., Sasazuki T., Samiotaki M., Panayotou G. Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation. J Proteomics 2012, 75:5356-5369.
75. Lim J.W.E., Mathias R.A., Kapp E.A., Layton M.J., Faux M.C., Burgess A.W., et al. Restoration of full-length APC protein in SW480 colon cancer cells induces exosome-mediated secretion of DKK-4. Electrophoresis 2012, 33:1873-1880.
76. Tauro B.J., Greening D.W., Mathias R.A., Ji H., Mathivanan S., Scott A.M., et al. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 2012, 56:293-304.
77. Balog C.I.A., Stavenhagen K., Fung W.L.J., Koeleman C.A., McDonnell L.M., Verhoeven A., et al. N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics 2012, 11:571-585.
78. Huang L.-Y. S100A4 over-expression underlies lymph node metastasis and poor prognosis in colorectal cancer. WJG 2011, 17:69.
79. Murakoshi Y., Honda K., Sasazuki S., Ono M., Negishi A., Matsubara J., et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci 2010, 102:630-638.
80. Zhang X., Xiao Z., Liu X., Du L., Wang L., Wang S., et al. The potential role of ORM2 in the development of colorectal cancer. PLoS One 2012, 7:e31868.
81. Tsai M.-H., Wu C.-C., Peng P.-H., Liang Y., Hsiao Y.-C., Chien K.-Y., et al. Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. J Mol Med 2011, 90:187-200.